Home Cart Sign in  
Chemical Structure| 54-85-3 Chemical Structure| 54-85-3

Structure of Isoniazid
CAS No.: 54-85-3

Chemical Structure| 54-85-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Isonicotinic acid hydrazide is an antibacterial agent used primarily as a tuberculostatic by blocking the action of fatty acid synthase by interacting with KatG.

Synonyms: INH; Isonicotinic acid hydrazide; Isoniazid, Isonicotinylhydrazide, Hydra, Hyzyd, Isovit, Nydrazid

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations      Show More

Hegde, Pooja Venkatesh ;

Abstract: Tuberculosis (TB) remains a leading cause of infectious disease mortality and morbidity resulting in nearly 1.3 million deaths annually and infecting nearly one-quarter of the population. Chapter 1 discusses the epidemiology, control, and management of TB. Isoniazid (INH) is a cornerstone for the treatment of drug-susceptible TB, yet the quantitative structure-activity relationships for INH are not well documented in the literature. Chapter 2 evaluates a systematic series of INH analogs against contemporary Mycobacterium tuberculosis (Mtb) strains from different lineages and several key species of non-tuberculous mycobacteria (NTM). To assess the specific activity of this series of INH analogs against mycobacteria, we assayed them against a panel of Gram-positive and Gram-negative bacteria, as well as a number of fungi. Our findings provide an updated analysis of the structure-activity relationship of INH that will serve as a valuable resource for the development of a next generation antitubercular compounds. para-Aminosalicylic acid (PAS), is an important second-line agent for treating drug-resistant Mtb. PAS has a moderate bioavailability and rapid clearance that necessitate high doses in order to facilitate an effective treatment. Consequently, such high doses commonly results in gastrointestinal disturbances (presumably by disruption of gut microbiota and host epithelial cells). Chapter 3 discusses the design, synthesis and evaluation of PAS prodrugs and analogs with improved oral bioavailability, thereby preventing intestinal accumulation as well as undesirable bioactivation by the gut microbiome to cytotoxic folate species. The pivoxyl prodrug and fluorination at the 5- position address the primary limitations of PAS and have the potential to revitalize this second-line TB drug. vi Pyrazinamide (PZA) is a critical component of the first-line TB treatment regimen because of its sterilizing activity against non-replicating Mtb, but its mechanism of action has remained enigmatic. PZA is a prodrug converted to the active moiety- pyrazinoic acid (POA), by pyrazinamidase, an amidase within the nicotinamide adenine dinucleotide (NAD) salvage pathway encoded by pncA in Mtb. PZA resistance is most commonly induced via loss-of-function mutations within PncA. It has recently been demonstrated that POA induces targeted protein degradation of the enzyme PanD, a crucial component of the coenzyme A biosynthetic pathway, essential in Mtb. Chapter 4 describes the structure activity relationship (SAR) evaluation of various POA analogs. Further development and mechanistic analysis of these analogs may lead to a next generation POA analog for treating TB. The salicylic acid derived small molecule siderophores known as mycobactins are essential for mycobacterial iron acquisition and mycobactin biosynthesis has been biochemically and genetically validated as essential for survival in vivo. Sal-AMS, a modified nucleoside derivative that mimics an intermediate in the mycobactin biosynthetic pathway, is a potent Mtb inhibitor. Chapter 5 explores polyfluorinated salicylic acid derivatives as antimetabolites, designed to antagonize mycobactin synthesis. Enzymatic studies demonstrated that the tri- and tetra- fluorinated salicylic acid analogs were neither substrates nor inhibitors of MbtA, but the di-fluorinated compounds were readily activated by the bifunctional adenylating enzyme MbtA, responsible for processing salicylic acid moieties for synthesis of mycobactins. However further microbiological analysis revealed that the polyfluorinated derivatives have low potential as anti-TB agents and do not appear to operate by inhibiting mycobactin synthesis. vii Lastly, the chemical synthesis of nucleoside analogs, an important class of compounds with applications as anti-infective, anti-cancer, and diagnostic agents, is extremely challenging, typically requiring linear synthesis, multiple protectiondeprotection sequences, and stereoselective formation of the critical glycosidic linkage. Nucleoside phosphorylases (NPs) have tremendous biocatalytic potential and aid in the selective modification of nucleosides under green conditions. Chapter 6 focuses on the functional characterization of 15 thermostable purine NPs. Four of these were further selected for a comprehensive analysis of their substrate scope. Next, chemoenzymatic methods for the synthesis of modified nucleosides were extensively studied using various coupled systems, and 12 modified nucleosides were synthesized, isolated, and characterized. viii Table of Contents Acknowledgments......................

Purchased from AmBeed: ; ; ; ; ; ;

Hegde, Pooja ; Boshoff, Helena I. M. ; Rusman, Yudi ; Aragaw, Wassihun Wedajo ; Salomon, Christine E. ; Dick, Thomas , et al.

Abstract: Isoniazid (INH) remains a cornerstone for treatment of drug susceptible tuberculosis (TB), yet the quant. structure-activity relationships for INH are not well documented in the literature. In this paper, we have evaluated a systematic series of INH analogs against contemporary Mycobacterium tuberculosis strains from different lineages and a few non-tuberculous mycobacteria (NTM). Deletion of the pyridyl nitrogen atom, isomerization of the pyridine nitrogen to other positions, replacement of the pyridine ring with isosteric heterocycles, and modification of the hydrazide moiety of INH abolishes antitubercular activity. Similarly, substitution of the pyridine ring at the 3-position is not tolerated while substitution at the 2-position is permitted with 2-methyl-INH 9 displaying antimycobacterial activity comparable to INH. To assess the specific activity of this series of INH analogs against mycobacteria, we assayed them against a panel of gram-pos. and gram-neg. bacteria, as well as a few fungi. As expected INH and its analogs display a narrow spectrum of activity and are inactive against all non-mycobacterial strains evaluated, except for 4, which has modest inhibitory activity against Cryptococcus neoformans. Our findings provide an updated anal. of the structure-activity relationship of INH that we hope will serve as useful resource for the community.

Keywords: Isoniazid ; SAR

Purchased from AmBeed: ; ; ; ; 54-92-2 ; ; ;

Alternative Products

Product Details of Isoniazid

CAS No. :54-85-3
Formula : C6H7N3O
M.W : 137.14
SMILES Code : NNC(=O)C1=CC=NC=C1
Synonyms :
INH; Isonicotinic acid hydrazide; Isoniazid, Isonicotinylhydrazide, Hydra, Hyzyd, Isovit, Nydrazid
MDL No. :MFCD00006426
InChI Key :QRXWMOHMRWLFEY-UHFFFAOYSA-N
Pubchem ID :3767

Safety of Isoniazid

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315
Precautionary Statements:P264-P270-P280-P301+P312+P330-P302+P352-P332+P313-P362+P364-P501

Isoform Comparison

Biological Activity

Description
Isoniazid (INH) functions as a proagent that requires activation by a specific bacterial enzyme called catalase-peroxidase, named KatG in Mycobacterium tuberculosis, to exert its effects. It is bactericidal against rapidly dividing mycobacteria, exhibiting anti-tuberculostatic activity, but acts as a bacteriostatic agent against slow-growing mycobacteria[1].[2].[3].[4].

In Vitro:

Cell Line
Concentration Treated Time Description References
Mtb H37Rv 0.5 μM To assess the bactericidal activity of NITD-916 against Mtb H37Rv. Results showed rapid killing at concentrations greater than 0.2 μM. Sci Transl Med. 2015 Jan 7;7(269):269ra3.
Human macrophages 1 μg/ml 24 hours To assess the bactericidal effect of isoniazid on Mtb in human macrophages. Results showed that at a dose of 1 μg/ml, only 2-4% of Mtb survived. Nat Commun. 2020 Jun 16;11(1):3062.
Mtb starved in PBS 0.5 µg/ml 7 days Evaluate the bactericidal effect of isoniazid under nutrient starvation conditions; the ΔcinA mutant was significantly killed by isoniazid in PBS starvation, while wild-type Mtb was unaffected. Nat Commun. 2022 Apr 22;13(1):2203.
Primary mouse bone marrow-derived macrophages (BMDM) 0.1 µg/ml 96 hours Evaluate the bactericidal effect of isoniazid in macrophages; the ΔcinA mutant was significantly killed by isoniazid in IFNγ-activated macrophages, while wild-type Mtb was unaffected. Nat Commun. 2022 Apr 22;13(1):2203.
HCT-116 cells 10 mM 24 hours Induced significant increase in histone and non-histone Kinic levels Nat Commun. 2021 Sep 20;12(1):5548.
HEK293A cells 10 mM 24 hours Induced significant increase in histone and non-histone Kinic levels Nat Commun. 2021 Sep 20;12(1):5548.
HepG2 cells 10 mM 24 hours Identification of histone isonicotinylation sites, revealing 26 unique histone Kinic sites Nat Commun. 2021 Sep 20;12(1):5548.
Adipose-derived mesenchymal stem cells (ADSCs) 0.5, 1, 5 μg/ml 24 hours To evaluate the drug tolerance of Mtb in ADSCs to isoniazid. Results showed that even at high doses of 5 μg/ml, approximately 5% of Mtb survived after INH treatment. At doses of 0.5 and 1 μg/ml, about 10-15% of Mtb were not killed. Nat Commun. 2020 Jun 16;11(1):3062.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Humanized PXR mouse model Oral 400 mg/L 4 weeks To investigate the hepatotoxicity caused by co-treatment of isoniazid and rifampicin, significant liver injury was observed in humanized PXR mice, characterized by increased serum ALT and ALP activities and bile plugs in the liver. Nat Med. 2013 Apr;19(4):418-20
BALB/c mice Acute and established Mycobacterium tuberculosis infection models Oral 25 mg/kg Daily dosing for 4 weeks To evaluate the in vivo efficacy of NITD-916 in acute and established Mycobacterium tuberculosis infection models. Results showed significant bactericidal activity at 100 mg/kg in both models. Sci Transl Med. 2015 Jan 7;7(269):269ra3.
BALB/c mice and athymic nude mice Mycobacterium tuberculosis H37Rv infection model Oral gavage 10 mg/kg 5 days per week, for 3 to 12 months To evaluate the bactericidal effect and relapse prevention of Isoniazid-containing regimens in immune-deficient mice. Results showed that rifapentine-containing regimens achieved sterilization in 3-6 months, while rifampin-containing regimens led to Isoniazid resistance in nude mice. Am J Respir Crit Care Med. 2011 May 1;183(9):1254-61
Mice C57BL/6 background mice Oral gavage 50 mg/kg/day Once daily for ten days Increased histone and non-histone Kinic levels in liver tissues of mice after INH treatment Nat Commun. 2021 Sep 20;12(1):5548.
C57BL/6 mice Tuberculosis infection model Oral gavage 10 mg/kg Once daily for 4 to 8 weeks To evaluate the therapeutic effect of isoniazid on tuberculosis in vivo. Results showed that INH treatment significantly reduced bacterial load in the lungs and spleen, especially after 8 weeks of treatment. The combination of celecoxib and INH showed a more significant reduction in bacterial load at both 4 and 8 weeks post-treatment. Nat Commun. 2020 Jun 16;11(1):3062.
BALB/c mice Mouse model of TB Oral gavage 0.5, 1.5 and 6.0 mg/kg/day 5 days per week for 42 days To evaluate the virulence and INH resistance of the ΔsigI mutant in a mouse model, results showed that the ΔsigI mutant was more virulent than wild-type and had higher survival in the presence of INH Nat Commun. 2012 Mar 20;3:753
Mice Tuberculosis model Oral 70 mg/kg Five days a week for four weeks To evaluate the therapeutic effect of isoniazid combined with rifampicin in tuberculosis-infected mice, results showed that nebulized cellulase enhanced the antimycobacterial activity of isoniazid and rifampicin Nat Commun. 2021 Mar 11;12(1):1606
BALB/c mice Mouse model of tuberculosis Oral 25 and 50 mg/kg (daily and thrice-weekly administration) Administered daily (5/7) or thrice-weekly (3/7) for 8, 10, or 12 weeks To evaluate the bactericidal activity and treatment-shortening potential of isoniazid in rifapentine-based regimens. Results showed that daily or thrice-weekly PHZ regimens achieved stable cure within 10-12 weeks. Am J Respir Crit Care Med. 2008 Nov 1;178(9):989-93
C57BL/6 mice Chronic tuberculosis infection model Drinking water 10 mg/kg/day, 5 mg/kg/day, 2.5 mg/kg/day 12 weeks Evaluate the bactericidal effect of isoniazid in chronically infected mice; the ΔcinA mutant was significantly killed by isoniazid during the chronic phase, while the killing effect on wild-type Mtb was poor. Nat Commun. 2022 Apr 22;13(1):2203.

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02114684 Recurrent Tuberculosis Phase 1 Phase 2 Completed - South Africa ... More >> CAPRISA eThekwini Clinical Research Site (eCRS) Durban, KwaZulu Natal, South Africa, 4001 Less <<
NCT00018083 Tuberculosis ... More >>HIV Infections Less << Not Applicable Unknown - United States, North Carolina ... More >> Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: Carol D Hamilton, M.D.    919-684-3279 Less <<
NCT02381470 Tuberculosis Phase 2 Not yet recruiting March 2018 Philippines ... More >> Lung Center Philippines Not yet recruiting Manila, Philippines Contact: Vincent Balanag          Principal Investigator: Vincent Balanag          Philippines Tuberculosis Society (Quezon Institute) Not yet recruiting Manila, Philippines Contact: Jubert Benedicto          Principal Investigator: Jubert Benedicto          Singapore Changi General Hospital Not yet recruiting Singapore, Singapore Contact: Augustine Tee          Principal Investigator: Augustine Tee          National University Hospital, Singapore Not yet recruiting Singapore, Singapore Contact: Meera Gurumurthy    +65 6772 7861    meera@nuhs.edu.sg    Principal Investigator: Nicholas Paton Less <<
NCT02953847 Tuberculosis Phase 1 Completed - South Africa ... More >> Clinical Research Centre Cape Town, Western Cape, South Africa, 7725 Less <<
NCT02279875 Pulmonary Tuberculosis Phase 2 Completed - South Africa ... More >> TASK Clinical Research Centre Bellville, Cape Town, South Africa, 7530 University of Cape Town Lung Institute (Pty) Ltd Mowbray, Cape Town, South Africa, 7700 Less <<
NCT03281226 Tuberculosis, Pulmonary ... More >> HIV/AIDS Less << Phase 2 Recruiting December 2019 Brazil ... More >> Fundação de Medicina Tropical Dr. Heitor Vieira Dourado Recruiting Manaus, Amazonas, Brazil, 69040000 Contact: Izabella P Safe, MD    (+55 92) 2127 3498    izabellasafe@gmail.com    Principal Investigator: Marcelo C dos Santos, MD, PhD Less <<
NCT03561753 Pulmonary Tuberculosis TB in S... More >>putum: (+) Microscopy Less << Phase 4 Recruiting December 31, 2021 China ... More >> Eighty-fifth Hospital of PLA Recruiting Shanghai, China, 200000 Contact: wang hui    +86021-81818585       Shanghai Public Health Clinical Center Shanghai, China Recruiting Shanghai, China, 200000 Contact: shen xin    +86021-37990333       Shanghai Center for Disease Control and Prevention Recruiting Shanghai, China, 200336 Contact: shan xin    +8602162758710       Shanghai Pulmonary Hospital, Shanghai, China Recruiting Shanghai, China, 200433 Contact: sha wei    +8602165115006 ext 2017    13671758200@126.com    Contact: liu yidian    +8602165115006 ext 2011    13816676933@139.com Less <<
NCT00376012 Tuberculosis ... More >>Human Immunodeficiency Virus Infections Less << Phase 3 Unknown September 2008 India ... More >> Tuberculosis Research Centre Chennai, Tamilnadu, India, 600 031 Less <<
NCT00130247 Tuberculosis Phase 3 Completed - Brazil ... More >> Universidade Federal do Espirito Santo - Duke Hubert-Yeargan Center Vitória, Espírito Santo, Brazil, 29040-091 Philippines Makati Medical Center Makati, National Capital Region, Philippines, 1229 Uganda Mulago Hospital Complex Kampala, Uganda, 99999 Less <<
NCT00760149 Tuberculosis Phase 2 Completed - Tanzania ... More >> Kibong'oto National Tuberculosis Hospital Sanya Juu, Kilimanjaro, Tanzania, P.O. box 12 Less <<
NCT02581527 Pulmonary Tuberculosis Phase 3 Recruiting December 2020 Botswana ... More >> University of Botswana Recruiting Gaborone, Botswana Peru Hospital Nacional Dos de Mayo Recruiting Lima, Peru Uganda Epicentre Recruiting Mbarara, Uganda Contact: Daniel Atwine          United Kingdom St. George's, University of London Not yet recruiting London, United Kingdom, SW17 0RE Contact: Amina Jindani, MD    020 8725 2810    ajindani@sgul.ac.uk    Contact: Tom Harrison, MD    020 8725 0447    tharriso@sgul.ac.uk Less <<
NCT01934309 Tuberculosis Not Applicable Completed - Kenya ... More >> AMPATH Eldoret, Kenya Less <<
NCT00140309 Tuberculosis, Pulmonary Phase 2 Completed - -
NCT01392911 Pulmonary Tuberculosis (TB) Phase 2 Completed - South Africa ... More >> TASK Applied Science Bellville, South Africa, 7531 University of Cape Town Lung Institute Mowbray, South Africa, 7700 Less <<
NCT01245036 Sarcoidosis T... More >>uberculosis Less << Not Applicable Completed - India ... More >> Deaprtment of Pulmonary Medicine, PGIMER Chandigarh, India, 160012 Less <<
NCT00000959 HIV Infections ... More >> Tuberculosis Less << Not Applicable Completed - United States, California ... More >> UCLA Med Ctr Los Angeles, California, United States, 90095 Community Consortium of San Francisco San Francisco, California, United States, 94110 United States, Colorado Denver CPCRA / Denver Public Hlth Denver, Colorado, United States, 80204 United States, Connecticut Hill Health Corp New Haven, Connecticut, United States, 06519 United States, Delaware Wilmington Hosp / Med Ctr of Delaware Wilmington, Delaware, United States, 19899 United States, District of Columbia Veterans Administration Med Ctr / Regional AIDS Program Washington, District of Columbia, United States, 20422 United States, Georgia AIDS Research Consortium of Atlanta Atlanta, Georgia, United States, 30308 United States, Louisiana Louisiana Comm AIDS Rsch Prog / Tulane Univ Med New Orleans, Louisiana, United States, 70112 United States, Michigan Comprehensive AIDS Alliance of Detroit Detroit, Michigan, United States, 48201 United States, New Jersey North Jersey Community Research Initiative Newark, New Jersey, United States, 07103 United States, New York Bronx Lebanon Hosp Ctr Bronx, New York, United States, 10456 Addiction Research and Treatment Corp Brooklyn, New York, United States, 11201 Clinical Directors Network of Region II New York, New York, United States, 10011 Harlem AIDS Treatment Group / Harlem Hosp Ctr New York, New York, United States, 10037 Less <<
NCT00767975 Tuberculosis Phase 3 Completed - Taiwan ... More >> Taipei Prison Taoyuan, Taiwan Less <<
NCT03474029 Latent Tuberculosis Phase 2 Phase 3 Not yet recruiting December 2020 -
NCT00402610 HIV Infections ... More >> Tuberculosis Less << Phase 4 Completed - Spain ... More >> Hospital Universitario Reina Sofía Córdoba, Spain, 14002 Less <<
NCT02457208 Tuberculosis Phase 1 Completed - Thailand ... More >> Shoklo Malaria Research Unit Mae Sot, Tak, Thailand, 63110 Less <<
NCT00023387 Tuberculosis Not Applicable Completed - -
NCT01154959 Pulmonary Tuberculosis Phase 3 Unknown February 2015 India ... More >> Tuberculosis Research Centre Recruiting Chennai, Tamilnadu, India, 600031 Contact: Subash Babu, MBBS, PhD    91-44-28369711    sbabu@niaid.nih.gov    Contact: Pavan Kumar, MSc    91-44-28369766    pavankumarn@trcchennai.in    Principal Investigator: Subash Babu, MBBS, PhD Less <<
NCT00929786 - Completed - India ... More >> All India Institute of Medical Sciences New Delhi, Delhi, India, 110029 All India Institute of Medical Sciences New Delhi, India, 110029 Less <<
NCT03568383 Tuberculosis, MDR Phase 3 Not yet recruiting December 22, 2024 -
NCT03302299 Tuberculosis ... More >>HIV/AIDS Alcohol Abuse Less << Phase 4 Recruiting August 31, 2021 Uganda ... More >> Mbarara University of Science and Technology/Mbarara Regional Referral Hospital Recruiting Mbarara, Uganda Contact: Christine Ngabirano, BASS    +256 776 418691    ngachrissy28@gmail.com    Contact: Adah Tumwegamire, BCS    +256 774 319258    T_Adah@yahoo.com    Principal Investigator: Winnie R Muyindike, MBChB, MMED          Sub-Investigator: Julian Adong, MBChB Less <<
NCT02467608 Pulmonary Tuberculosis Phase 2 Phase 3 Unknown December 2017 Taiwan ... More >> Changhua Christian Hospital Recruiting Changhua, Taiwan Contact: Ching-Hsiung Lin, MD PhD          Changhua Hosiptal Ministry of Health And Welfare Recruiting Changhua, Taiwan Contact: Yi-Wen Huang, MD PhD          Chang Gung Memorial Hospital, ChiaYi Recruiting ChiaYi, Taiwan Contact: Meng-Jer Hsieh, MD          Chang Gung Memorial Hospital, Kaohsiung Recruiting Kaohsiung, Taiwan Contact: Wen-Feng Fang, MD          E-DA Hospital, I-Shou University Recruiting Kaohsiung, Taiwan Contact: Chun-Kai Huang, MD          Kaohsiung Medical University Hospital Recruiting Kaohsiung, Taiwan Contact: Inn-Wen Chong, MD          Kaohsiung Veterans General Hospital Recruiting Kaohsiung, Taiwan Contact: Susan Shin-Jung Lee, MD          Chang Gung Memorial Hospital ,Linkou Recruiting Linkou, Taiwan Contact: Shih-Wei Lin, MD          Taichung Veterans General Hospital Recruiting Taichung, Taiwan Contact: Wei-Chang Huang, MD          Taipei Veterans General Hospital Recruiting Taipei, Taiwan, 112 Contact: Wei-Jhen Su, MD          Tri-Service General Hospital Recruiting Taipei, Taiwan, 11490 Contact: Wann-Cherng Perng, MD PhD          Buddhist Tzu Chi General Hospital Recruiting Taipei, Taiwan Contact: Yao-Kuang Wu, MD          Cheng Hsin General Hospital Recruiting Taipei, Taiwan Contact: Wei-Teing Chen, MD PhD          National Taiwan University Hospital Recruiting Taipei, Taiwan Contact: Jann-Yuan Wang, MD PhD          Taipei City Hospital Terminated Taipei, Taiwan Taipei Medical University Hospital Recruiting Taipei, Taiwan Contact: Chi-Li Chung, MD PhD          Taipei Medical University-Shuang Ho Hospital Recruiting Taipei, Taiwan Contact: Chun-Nin Lee, MD          Taipei Wanfang Hospital Recruiting Taipei, Taiwan Contact: Ming-Chih Yu, MD Less <<
NCT00023413 HIV Infections ... More >> Tuberculosis Less << Phase 2 Completed - -
NCT01456845 - Completed - India ... More >> All India Institute of Medical Sciences New Delhi, India, 110029 Less <<
NCT00130247 - Completed - -
NCT02331823 Reinfection Pulmonary Tubercul... More >>osis Less << Phase 4 Unknown December 2016 China, Shanghai ... More >> Shanghai Pulmonary Hospital Recruiting Shanghai, Shanghai, China, 200433 Contact: Qing Zhang, M.D    8621-65115006 ext 2002    zhqi709851@sohu.com    Contact: Wei Sha, M.D    8621-65115006 ext 2017    shfksw@126.com    Sub-Investigator: Qing Zhang, M.d Less <<
NCT02875574 - Completed - United Kingdom ... More >> Royal Free London NHS Foundation Trust London, Greater London, United Kingdom, NW3 2QG Less <<
NCT02747654 NAT2 Genotype Not Applicable Unknown - Korea, Republic of ... More >> Samsung Medical Center Recruiting Seoul, Korea, Republic of, 135-710 Contact: Soo-Youn Lee Less <<
NCT01395654 Hepatitis Tub... More >>erculosis, Pulmonary Less << Phase 4 Unknown December 2015 Taiwan ... More >> Chest Hospital Recruiting Tainan, Taiwan Contact: Jung-Yien Chien    886-6-2705911 ext 3206    jychien@ntu.edu.tw    National Taiwan University Hospital Recruiting Taipei, Taiwan Contact: Jann-Yuan Wang    23123456    jywang@ntu.edu.tw Less <<
NCT01223534 Latent Tuberculosis Infection Phase 4 Completed - Spain ... More >> Bellvitge University Hospital, IDIBELL L'Hospitalet de Llobregat, Barcelona, Barcelona, Spain, 08907 Less <<
NCT00495651 HIV Infections ... More >> Tuberculosis Less << Phase 3 Completed - Côte D'Ivoire ... More >> Centre de prise en charge de personnes vivant avec le VIH la pierre angulaire Abidjan, Côte D'Ivoire Centre de Prise en Charge et de Formation ACONDA Abidjan, Côte D'Ivoire Centre de Suivi des donneurs de sang, Centre National de Transfusion Sanguine Abidjan, Côte D'Ivoire Centre Intégré de Recherches Biocliniques d'Abidjan Abidjan, Côte D'Ivoire Centre médico-social El Rapha Abidjan, Côte D'Ivoire Formation Sanitaire Urbaine Anonkoua Kouté Abidjan, Côte D'Ivoire Hopital Général Felix Houphouet Boigny Abidjan, Côte D'Ivoire Service des Maladies Infectieuses et Tropicales, CHU de Treichville Abidjan, Côte D'Ivoire Unité de Soins Ambulatoires et de Conseil, CHU de Treichville Abidjan, Côte D'Ivoire Less <<
NCT01782950 AIDS With Tuberculosis Phase 4 Unknown March 2016 Uganda ... More >> Infectious Diseases Institute Recruiting Kampala, Uganda, 256 Contact: Christine Sekaggya, MMed    +256312307000 ext 370    csekaggya@idi.co.ug    Principal Investigator: Barbara Castelnuovo, MBChB, PhD Less <<
NCT00728507 Tuberculosis Phase 2 Terminated(Funding withdrawn) - Brazil ... More >> Centro de Referência Professor Hélio Fraga - ENSP - FIOCRUZ Curicica, Rio de Janeiro, Brazil, 22.780-192 Posto de Saude Albert Sabin Rio de Janeiro, RJ, Brazil, 20211-110 Hospital Universitario Clementio Fraga Filho Rio de Janeiro, Brazil Less <<
NCT00728507 - Terminated(Funding withdrawn) - -
NCT01398618 Latent Tuberculosis Infection Phase 3 Unknown December 2013 Taiwan ... More >> Chest Hospital, Department of Health, Executive Yuan Tainan, Taiwan, 71742 National Taiwan University Hospital Taipei, Taiwan, 100 Less <<
NCT00396084 - Completed - -
NCT00396084 Tuberculosis Phase 1 Phase 2 Completed - United States, California ... More >> San Francisco General Hospital - Pulmonary and Critical Care Medicine San Francisco, California, United States, 94110-3518 Brazil Universidade Federal do Espirito Santo - Duke Hubert-Yeargan Center Vitória, Espírito Santo, Brazil, 29040-091 Less <<
NCT01582711 Latent Tuberculosis Infection Phase 3 Completed - United States, California ... More >> University of California, San Francisco San Francisco, California, United States, 94110 United States, Colorado Denver Public Health Department Denver, Colorado, United States, 80204 United States, District of Columbia Washington DC Veterans Affairs Medical Center Washington, District of Columbia, United States, 20422 United States, New York Columbia University College of Physicians and Surgeons and New York City Department of Health New York, New York, United States, 10032 United States, North Carolina Duke University Durham, North Carolina, United States, 27713 United States, Tennessee Vanderbilt University Medical Center and Nashville Metro Public Health Department Nashville, Tennessee, United States, 37232-0146 United States, Texas University of North Texas Health Science Center at Fort Worth Fort Worth, Texas, United States, 76104-4802 Audie L. Murphy VA Hospital San Antonio, Texas, United States, 78229-4404 South Texas - Department of State Health Services San Antonio, Texas, United States, 78229-4404 China TB and Chest service of Hong Kong Hong Kong, China South Africa Wits Health Consortium Soweto, South Africa Spain Agencia de Salut Publica - Barcelona, Spain and UNTHSC Barcelona, Spain, 08023 Less <<
NCT00298870 Pulmonary Tuberculosis Phase 4 Completed - Japan ... More >> Osaka Prefectural Medical Center for Respiratory and Allergic Diseases Habikino, Osaka, Japan, 583-8588 Osaka Hospital, Anti-Tuberculosis Association, Osaka Branch Neyagawa, Osaka, Japan, 572-0801 National Hospital Organization Kinki-chuo Chest Medical Center Sakai, Osaka, Japan, 591-8555 National Hospital Organization Toneyama Toyonaka, Osaka, Japan, 560-8552 Less <<
NCT01136161 Latent Tuberculosis Infection ... More >> Tuberculosis Less << Phase 2 Completed - South Africa ... More >> Parexel Int. Bloemfontein Bloemfontein, South Africa, 9301 Parexel Int. George George, South Africa, 6529 Parexel Int. Port Elizabeth Port Elizabeth, South Africa, 6045 Less <<
NCT00164450 Tuberculosis Not Applicable Completed - -
NCT01589497 Tuberculosis Phase 2 Completed - South Africa ... More >> University of Cape Town Lung Institute (UCTLI) CRS (31792) Cape Town, Western Cape, South Africa, 7705 TASK Applied Science CRS (31718) Bellville, South Africa, 7531 Less <<
NCT00351702 Human Immunodeficiency Virus ... More >> Tuberculosis Less << Phase 3 Completed - India ... More >> Tuberculosis Research Centre Chennai, Tamilnadu, India, 600 031 Less <<
NCT00023335 Pulmonary Tuberculosis Phase 3 Completed - -
NCT01589497 - Completed - -
NCT02735590 Tuberculosis Phase 2 Phase 3 Enrolling by invitation May 30, 2019 South Africa ... More >> Centre for the Aids Programme of Research in South Africa (CAPRISA) Durban, KwaZulu-Natal, South Africa, 4013 Aurum Institute Klerksdorp, North West Province, South Africa, 2571 Aurum Institute Rustenburg, North West, South Africa, 0300 Stellenbosch Immunology Research Group Cape Town, Western Cape, South Africa, 7505 South African Tuberculosis Vaccine Initiative (SATVI) Worcester, Western Cape, South Africa, 6850 Less <<
NCT02014272 - Completed - -
NCT01875952 Human Immunodeficiency Virus (... More >>HIV)|Tuberculosis (TB)|Latent Tuberculosis Infection (LTI) Less << PHASE4 UNKNOWN 2025-06-13 Instituto Nacional de Salud Pu... More >>blica, Mexico, Cuernavaca Morelos, 62100, Mexico|Clínica Especializada CONDESA, Mexico City, D.F, 06140, Mexico Less <<
NCT02014272 Healthy Volunteers Phase 1 Completed - Singapore ... More >> Pfizer Investigational Site Singapore, Singapore, 188770 Less <<
NCT00004740 Tuberculosis Not Applicable Unknown - -
NCT03498534 Latent Tuberculosis ... More >> Diabetes Mellitus Less << Phase 4 Withdrawn(Due to administrativ... More >>e procedures) Less << December 2013 -
NCT01119521 Tuberculosis Phase 1 Completed - South Africa ... More >> University of Cape Town - Institute of Infectious Disease and Molecular Medicine Cape Town, Western Cape, South Africa, 7925 Less <<
NCT00128206 - Completed - -
NCT00931736 Latent Tuberculosis Infection Phase 3 Completed - Australia, New South Wales ... More >> Woolcock Institute of Medical Research Sydney, New South Wales, Australia Benin Centre de Pneumophthysiologie Cotonou, Benin Brazil Universidade Gama Filho, Centro de Ciências Biológicas e da Saúde Rio de Janeiro, Brazil Canada, Alberta University of Alberta Edmonton, Alberta, Canada Canada, British Columbia British Columbia Centre for Disease Control Vancouver, British Columbia, Canada Canada, Quebec Montreal Chest Institute Montreal, Quebec, Canada, H2X 2P4 Canada, Saskatchewan Royal University Hospital Saskatoon, Saskatchewan, Canada Ghana Research and Development Unit, Komfo Anokye Teaching Hospital Kumasi, Ghana Guinea Service de Phtisiologie, Hopital National Ignace Deen Conakry, Guinea Indonesia Health Research Unit, Faculty of Medicine Bandung, West Java, Indonesia Korea, Republic of Korean Institute of Tuberculosis Seoul, Korea, Republic of Saudi Arabia King Fahad National Guard Hospital Riyadh, Saudi Arabia Less <<
NCT01399788 - Completed - -
NCT00000778 HIV Infections ... More >> Tuberculosis Less << Phase 1 Completed - United States, Alabama ... More >> Univ of Alabama at Birmingham Birmingham, Alabama, United States, 352336505 United States, California UCLA Med Ctr Los Angeles, California, United States, 900951793 Harbor - UCLA Med Ctr Torrance, California, United States, 90502 United States, Florida Broward Gen Med Ctr Fort Lauderdale, Florida, United States, 33316 Univ of Miami / Jackson Memorial Hosp Miami, Florida, United States, 33136 United States, Illinois Univ of Illinois Chicago, Illinois, United States, 60622 United States, Louisiana Tulane Univ Med School New Orleans, Louisiana, United States, 701122699 United States, Texas Univ of Texas Southwestern Med Ctr of Dallas Dallas, Texas, United States, 75235 Univ TX Galveston Galveston, Texas, United States, 77550 Baylor College of Medicine / Houston Veterans Adm Med Ctr Houston, Texas, United States, 77030 Less <<
NCT03315962 Tuberculosis ... More >>HIV/AIDS Less << Not Applicable Recruiting September 2021 Uganda ... More >> Infectious Diseases Research Collaboration Recruiting Kampala, Uganda Contact: Elijah Kakande, MBChB       rkakande@idrc-uganda.org    Principal Investigator: Dalsone Kwarisiima, MBChB Less <<
NCT00128206 Tuberculosis Phase 3 Completed - United States, California ... More >> University of California San Francisco San Francisco, California, United States, 94143-0608 Less <<
NCT02771249 Healthy Volunteers Phase 1 Recruiting December 31, 2019 United States, Maryland ... More >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)    800-411-1222 ext TTY8664111010    prpl@cc.nih.gov Less <<
NCT03510468 Healthy Volunteers Phase 1 Recruiting August 30, 2021 United States, Maryland ... More >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)    800-411-1222 ext TTY8664111010    prpl@cc.nih.gov Less <<
NCT03435146 Respiratory Tract Infections ... More >> HIV Infections Less << Phase 1 Phase 2 Recruiting November 3, 2018 South Africa ... More >> The Aurum Institute: Tembisa Clinical Research Centre Recruiting Tembisa, Gauteng, South Africa, 1736 Contact: Modulakgotla Sebe, BCh, MB    27-87-1351645    msebe@auruminstitute.org Less <<
NCT02651259 Tuberculosis Phase 1 Phase 2 Active, not recruiting March 31, 2019 Haiti ... More >> Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS Port-au-Prince, Haiti, HT-6110 Kenya Kenya Medical Research Institute / Walter Reed Project Clinical Research Center, Kericho CRS Kericho, Kenya, 20200 Malawi Malawi CRS Lilongwe, Central Malawi, Malawi Thailand Siriraj Hospital ,Mahidol University NICHD CRS Bangkok, Bangkoknoi, Thailand, 10700 Zimbabwe Harare Family Care CRS Harare, Zimbabwe Less <<
NCT01399788 Healthy Volunteers Phase 1 Completed - Singapore ... More >> Pfizer Investigational Site Singapore, Singapore, 188770 Less <<
NCT01404312 - Completed - -
NCT03334734 Tuberculosis Phase 2 Terminated(Very slow enrollmen... More >>t) Less << - -
NCT01404312 Tuberculosis ... More >>HIV Infections Less << Phase 3 Completed - -
NCT00864383 Pulmonary Tuberculosis Phase 3 Completed - -
NCT00728546 Tuberculosis ... More >>Hepatotoxicity Less << Phase 4 Unknown November 2015 Taiwan ... More >> National Taiwan University Hospital Recruiting Taipei, Taiwan, 100 Contact: Li-Jiuan Shen, Ph.D.    886-2-2312-3456 ext 8411    ljshen@ntu.edu.tw    Principal Investigator: Li-Jiuan Shen, Ph.D. Less <<
NCT00164463 Tuberculosis Phase 2 Completed - United States, California ... More >> University of Southern California Medical Center Los Angeles, California, United States, 90033 United States, Maryland Johns Hopkins University Baltimore, Maryland, United States, 21231 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Texas University of North Texas Health Science Center Fort Worth, Texas, United States, 76104 Houston Veterans Administration Medical Center Houston, Texas, United States, 77030 Audie L Murphy Memorial Veterans Administration Medical Center San Antonio, Texas, United States, 78284 Canada, British Columbia University of British Columbia Vancouver, British Columbia, Canada, V5Z 1L8 Uganda Makerere University Medical School Kampala, Uganda Less <<
NCT00293228 Tuberculosis Phase 4 Completed - Mexico ... More >> Instituto Nacional de Salud Pública Cuernavaca, Morelos, Mexico, 62508 Less <<
NCT03278483 Diabetes Mellitus ... More >> Tuberculin (Skin Test) Positive Less << Phase 4 Active, not recruiting July 15, 2019 Mexico ... More >> Instituto Nacional de Ciencias Medicas y Nutrición Mexico City, Mexico, 14000 Less <<
NCT00864383 - Completed - -
NCT02043314 Tuberculosis Phase 1 Completed - Brazil ... More >> Synchrophar - Ass. e Desenv. de Projetos Clínicos Ltda. Campinas, São Paulo, Brazil, 13070-200 Less <<
NCT00850915 Tuberculosis Phase 4 Completed - Kenya ... More >> Makuyu H/C Makuyu-Muranga, Central, Kenya Huruma Lions -Central district Nairobi, Nairobi North, Kenya Kangemi HC Nairobi, Nairobi North, Kenya Blue House, Mathare Nairobi, Nairobi South, Kenya Jericho HC Nairobi, Nairobi South, Kenya Kibera AMREF Nairobi, Nairobi South, Kenya MMM, Mukuru, Embakasi Nairobi, Nairobi South, Kenya Pumwani Majengo H/C Nairobi, Nairobi South, Kenya Remand H/C Nairobi, Nairobi South, Kenya Soweto Kayole, Embakasi Nairobi, Nairobi South, Kenya KAPSABET District Hospital Kapsabet-Nandi, North Rift, Kenya NYALENDA Kisumu district, Nyanza North, Kenya Kadem leprosy, Migori Migori District, Nyanza South, Kenya Muhuru Health centre, Migori Migori District, Nyanza South, Kenya Awendo SDH Rongo district, Nyanza South, Kenya Lanet Nakuru, RVS, Kenya Nakuru West Nakuru, RVS, Kenya Narok District Hosp Narok, RVS, Kenya Less <<
NCT02613169 Tuberculosis PHASE2 COMPLETED 2025-12-20 Kisumu County Hospital, Kisumu... More >>, Kenya Less <<
NCT03028129 Tuberculosis, Pulmonary ... More >> Antibiotic Prophylaxis Less << Phase 4 Recruiting September 2020 Brazil ... More >> Roberto Oliveira Recruiting Dourados, Mato Grosso Do Sul, Brazil, 78824210 Contact: Roberto D Oliveira, Master    +55 67 99142-3003    roberto@uems.br    Principal Investigator: Julio H Croda, PhD Less <<
NCT02231229 Tuberculosis Phase 4 Active, not recruiting June 2020 France ... More >> Bichat Claude Bernard Hospital Paris, France, 75018 Bichat hospital Paris, France, 75018 Less <<
NCT01311505 Tuberculosis Phase 1 Completed - Philippines ... More >> Pfizer Investigational Site Dasmariñas City, Philippines, 4114 Less <<
NCT00080119 HIV Infection ... More >> Tuberculosis Pneumocystis Jiroveci Pneumonia Less << Phase 2 Phase 3 Terminated(Data Safety Monitor... More >>ing Board (DSMB) recommended stopping study due to futility) Less << - Botswana ... More >> Princess Marina Hospital Gaborone, Botswana South Africa University of Cape Town, Red Cross Children's Hospital Cape Town, South Africa University of Stellenbosch, Tygerberg Hospital Cape Town, South Africa Nelson R. Mandela School of Medicine, University of KwaZulu Natal, Durban Durban, South Africa, 4001 Perinatal HIV Research Unit at Chris Hani Baragwanath Hospital Johannesburg, South Africa, 2013 Chris Hani Baragwanath Hospital, Harriet Shezi Clinic Johannesburg, South Africa Less <<
NCT00080119 - Terminated(Data Safety Monitor... More >>ing Board (DSMB) recommended stopping study due to futility) Less << - -
NCT01494038 HIV Infections ... More >> Tuberculosis Less << Phase 4 Completed - Botswana ... More >> Gaborone CRS Gaborone, Botswana Molepolole CRS Gaborone, Botswana Haiti Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS Port-au-Prince, Haiti, HT-6110 India Byramjee Jeejeebhoy Medical College (BJMC) CRS Pune, Maharashtra, India, 411001 South Africa Soweto IMPAACT CRS Johannesburg, Gauteng, South Africa, 1862 Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS Cape Town, Western Cape Province, South Africa, 7505 Fam-Cru Crs Cape Town, Western Cape Province, South Africa, 7505 Tanzania Kilimanjaro Christian Medical Centre (KCMC) Moshi, Tanzania Thailand Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS Chiang Mai, Thailand, 50200 Uganda MU-JHU Research Collaboration (MUJHU CARE LTD) CRS Kampala, Uganda Zimbabwe Seke North CRS Chitungwiza, Zimbabwe St Mary's CRS Chitungwiza, Zimbabwe Harare Family Care CRS Harare, Zimbabwe Less <<
NCT00397709 Tuberculosis Phase 4 Terminated - Spain ... More >> Maria Paloma Geijo Martinez. Hospital Virgen de la Luz Cuenca, Spain, 16002 Less <<
NCT01936831 Tuberculosis Early Phase 1 Recruiting March 15, 2019 South Africa ... More >> TASK Applied Science CRS (31718) Recruiting Bellville, South Africa, 7531 Contact: Jeannine du Bois, MB, ChB       dr.jeannine@task.org.za    Principal Investigator: Andreas Diacon, MD, PhD Less <<
NCT00330304 Tuberculosis Phase 3 Unknown July 2011 South Africa ... More >> Red Cross Childrens Hospital Cape Town, Western Cape, South Africa, 7700 Tygerberg Hospital Cape Town, Western Cape, South Africa Less <<
NCT01494038 - Completed - -
NCT00513396 Tuberculosis, Multidrug-Resist... More >>ant Less << Phase 2 Phase 3 Completed - -
NCT03730181 Latent Tuberculosis Phase 1 Phase 2 Not yet recruiting February 2022 -
NCT00023374 Tuberculosis Not Applicable Completed - -
NCT00023348 HIV Infections ... More >> Tuberculosis Less << Phase 2 Phase 3 Completed - -
NCT00170209 Latent Tuberculosis Infection Phase 3 Completed - Australia, New South Wales ... More >> Woolcock Institute of Medical Research Sydney, New South Wales, Australia Benin Centre de Pneumophthysiologie Cotonou, Benin Brazil Universidade Gama Filho, Centro de Ciências Biológicas e da Saúde Rio de Janeiro, Brazil Canada, Alberta University of Alberta Edmonton, Alberta, Canada Canada, British Columbia British Columbia Centre for Disease Control Vancouver, British Columbia, Canada Canada, Quebec Montreal Children's Hospital Montreal, Quebec, Canada, H2X 2P4 Ghana Research and Development Unit, Komfo Anokye Teaching Hospital Kumasi, Ghana Guinea Service de Pneumo-Phtisiologie, Hopital National Ignace Deen Conakry, Africa, Guinea Indonesia Health Research Unit, Faculty of Medicine Bandung, West Java, Indonesia Less <<
NCT00130325 Tuberculosis Not Applicable Completed - Gambia ... More >> MRC Laboratories Banjul, Ksmd, Gambia, Po Box 273 Banjul Less <<
NCT02430259 Silicosis Tub... More >>erculosis Less << Phase 3 Unknown December 2018 China, Zhejiang ... More >> Wenling No.1 People's Hospital, Zhejiang Recruiting Taizhou, Zhejiang, China, 317500 Contact: Xuefeng Liu, MD    +86576-86206803    lhpxf@163.com    Sub-Investigator: Xitian Huang, MD Less <<
NCT01311505 - Completed - -
NCT03266991 Compliance, Patient Phase 4 Recruiting January 2020 Denmark ... More >> Dept of Pulmonary Medicine Recruiting Aarhus, Denmark, 8000 Contact: Nina B Staerke, MD       ninase@rm.dk    Dept of Pulmonary Medicine Recruiting Esbjerg, Denmark, 6700 Contact: Torben Jensen, MD Less <<
NCT01087190 Kidney Transplant Recipient Not Applicable Completed - Korea, Republic of ... More >> Asan Medical Center Seoul, Korea, Republic of, 138-736 Less <<
NCT01926379 HIV Tuberculo... More >>sis Less << Not Applicable Unknown May 2017 Ethiopia ... More >> Addis Ketema Health Center Dire Dawa, Ethiopia Dire Dawa Health Center Dire Dawa, Ethiopia Gende Gerada Health Center Dire Dawa, Ethiopia Gende Kore Health Center Dire Dawa, Ethiopia Goro Health Center Dire Dawa, Ethiopia Legehare Health Center Dire Dawa, Ethiopia Melka-Jebdu Health Center Dire Dawa, Ethiopia Sabian Health Center Dire Dawa, Ethiopia Arategna Health Center Harar, Ethiopia Jinela Health Center Harar, Ethiopia Less <<
NCT00023452 Tuberculosis Phase 3 Completed - -
NCT00463086 Tuberculosis ... More >>Latent Tuberculosis Infection HIV Infections Less << Not Applicable Completed - South Africa ... More >> Ubuntu Clinic,Site B Khayelitsha Cape Town, Western Cape, South Africa Less <<
NCT01761201 Latent Tuberculosis Infection ... More >> Infection in Solid Organ Transplant Recipients Less << Phase 3 Terminated(Recruitment rythm n... More >>ot sufficent to reach the simple size needed.) Less << - Spain ... More >> Complejo Hospitalario de Albacete Albacete, Spain Hospital Infanta Cristina, Badajoz, Spain Hospital Clinic Barcelona, Spain Hospital Vall d'Hebron Barcelona, Spain Hospital de Cruces Bilbao, Spain Complejo Hospitalario Universitario Coruña, Spain Hospital Reina Sofía Córdoba, Spain Hospital universitario Virgen de las Nieves Granada, Spain Hospital 12 de Octubre Madrid, Spain Hospital Gregorio Marañón Madrid, Spain Hospital Ramón y Cajal Madrid, Spain Hospital Universitario Puerta de Hierro Madrid, Spain Hospital Virgen de la Arrixaca Murcia, Spain Hospital Universitario Carlos Haya Málaga, Spain Clínica Universitaria de Navarra Pamplona, Spain Hospital Marqués de Valdecillas Santander, Spain Hospital Virgen del Rocío Seville, Spain Hospital Universitario La Fe Valencia, Spain Less <<
NCT01550705 Erythropoietic Protoporphyria ... More >>(EPP)|X Linked Erythropoietic Protoporphyria Less << TERMINATED 2025-12-15 University of Utah School of M... More >>edicine, Salt Lake City, Utah, 84132, United States Less <<
NCT02208427 Latent Tuberculosis Infection Phase 3 Unknown December 2016 Taiwan ... More >> National Taiwan University Hospital Taipei, Taiwan, 100 Less <<
NCT01550705 Erythropoietic Protoporphyria ... More >>(EPP)|X Linked Erythropoietic Protoporphyria Less << TERMINATED 2025-12-15 University of Utah School of M... More >>edicine, Salt Lake City, Utah, 84132, United States Less <<
NCT02076685 Hepatotoxicity Not Applicable Unknown November 2015 Taiwan ... More >> National Taiwan University Hospital Recruiting Taipei, Taiwan Contact: Li-Jiuan Shen, Ph.D.       ljshen@ntu.edu.tw    Principal Investigator: Li-Jiuan Shen, Ph.D. Less <<
NCT02980016 Tuberculosis ... More >>HIV Less << Phase 3 Active, not recruiting September 2019 South Africa ... More >> The Aurum Institute NPC Johannesburg, Gauteng, South Africa, 2193 Less <<
NCT00144417 Tuberculosis Phase 2 Completed - -
NCT00164281 Tuberculosis|HIV Infections PHASE4 COMPLETED 2025-05-11 Gaborone and Francistown Healt... More >>h Clinics, Gaborone and Francistown, Botswana Less <<
NCT00571753 Pulmonary Tuberculosis Phase 3 Terminated(Enrolling participa... More >>nts has halted prematurely due to a low recruitment rate.) Less << February 2012 Bulgaria ... More >> Specialized Hospital for Active Treatment of Pulmonary Diseases "Sveta Sofia" Sofia, Bulgaria, 1431 Germany Zentralkrankenhaus Bad Berka GmbH Bad Berka, Germany, 99437 Karl-Hansen-Klinik Bad Lippspringe, Germany, 33175 Helios Klinikum Emil von Behring GmbH Berlin, Germany, 14165 Medizinische Klinik I, Abteilung Pneumologie/Allergologie, Universitätsklinikum Frankfurt am Main Frankfurt am Main, Germany, 60590 Abteilung Innere Medizin/ Pneumologie, Thoraxklinik am Universitätsklinikum Heidelberg Heidelberg, Germany, 69126 Lungenfachklinik Immenhausen Immenhausen, Germany, 34376 Department I of Internal Medicine, University Hospital, University of Cologne Köln, Germany, 50931 Diakoniekrankenhaus Rotenburg Rotenburg, Germany, 27356 Division of Infectious Diseases and Clinical Immunology, Department of Internal Medicine Ulm, Germany, 89081 Poland Specialized Hospital of Lung Diseases and Tuberculosis in Wielkopolska in Chodzież Chodzież, Poland, 64-800 Department of Pulmonal Diseases, K. Marcinkowski University of Medical Sciences Poznan, Poland, 60-569 Less <<
NCT03665402 Tuberculosis|Drug-Induced Live... More >>r Injury|Adverse Drug Event Less << COMPLETED 2019-03-31 Seoul National University Hosp... More >>ital Clinical Trials Center, Seoul, 110-744, Korea, Republic of Less <<
NCT00023452 - Completed - -
NCT02832778 HIV Phase 1 Recruiting February 2018 Uganda ... More >> Infectious Diseases Insitute Not yet recruiting Kampala, P.O. Box 22418, Uganda Contact: Mohammed Lamorde, MBBS, MRCP, PhD    +256 312 307 000    mlamorde@idi.co.ug    United Kingdom Chelsea and Westminster Hospital NHS Foundation Trust Recruiting London, United Kingdom, SW10 9NH Contact: Marta Boffito    0208 846 6507    marta.boffito@chelwest.nhs.uk Less <<
NCT03069807 Latent Tuberculosis Not Applicable Recruiting April 2019 United Kingdom ... More >> Shrewsbury Road Health Centre Recruiting London, United Kingdom, E7 8QP Contact: Heinke Kunst       h.kunst@qmul.ac.uk    Contact: Matthew Burman       m.burman@qmul.ac.uk Less <<
NCT01215851 Pulmonary Tuberculosis Phase 2 Completed - South Africa ... More >> Centre for Tuberculosis Research Innovation, UCT Lung Institute Cape Town, South Africa, 7700 Task Applied Science, Karl Bremer Hospital Cape Town, South Africa Less <<
NCT00633256 Smoking Not Applicable Completed - United States, Connecticut ... More >> West Haven VA West Haven, Connecticut, United States, 06516 Less <<
NCT00633256 - Completed - -
NCT02383849 - Enrolling by invitation March 2020 South Africa ... More >> Soweto IMPAACT CRS (8052) Johannesburg, Gauteng, South Africa, 1862 Family Clinical Research Unit (FAM-CRU) CRS (8950) Tygerberg, Western Cape Province, South Africa, 7505 Less <<
NCT01043575 Smear Positive, Pan-sensitive,... More >> Pulmonary Tuberculosis Less << Phase 2 Completed - United States, Colorado ... More >> Denver Public Health Denver, Colorado, United States United States, Texas University of North Texas Denton, Texas, United States TBTC site 40 / South Texas Harlingen, Texas, United States Audie L. Murphy VA Medical Center San Antonio, Texas, United States South Africa University of KwaZulu Natal Durban, South Africa Uganda Uganda / Case Western Reserve Research Collaboration Kampala, Uganda Less <<
NCT03625739 - Recruiting December 31, 2026 China ... More >> Beijing Children's Hospital of Capital Medical University Recruiting Beijing, China Contact: Adong Shen, Master    13370115087    shenad16@hotmail.com Less <<
NCT03230409 Tuberculosis Not Applicable Completed - -
NCT03678688 Pulmonary TB Phase 1 Phase 2 Recruiting October 2020 South Africa ... More >> TASK Clinical Research Centre Recruiting Cape Town, South Africa, 7530 Contact: Veronique R de Jager, MD    +27(0) 21 917 1044    dr.veronique@task.org.za    University of Cape Town Lung Institute Recruiting Cape Town, South Africa, 7700 Contact: Prof. Rodney Dawson, MD    +27(0) 21 406 6850    rodney.dawson@uct.ac.za Less <<
NCT00004736 HIV Infections ... More >> Tuberculosis Less << Phase 1 Completed - United States, California ... More >> Univ of Southern California / LA County USC Med Ctr Los Angeles, California, United States, 900331079 Univ of California / San Diego Treatment Ctr San Diego, California, United States, 921036325 United States, Illinois Cook County Hosp Chicago, Illinois, United States, 60612 United States, New York Beth Israel Med Ctr New York, New York, United States, 10003 Bellevue Hosp / New York Univ Med Ctr New York, New York, United States, 10016 Columbia Presbyterian Med Ctr New York, New York, United States, 10032 United States, Pennsylvania Univ of Pennsylvania at Philadelphia Philadelphia, Pennsylvania, United States, 19104 United States, Rhode Island Brown Univ / Miriam Hosp Providence, Rhode Island, United States, 02906 Miriam Hosp / Brown Univ Providence, Rhode Island, United States, 02906 United States, Tennessee Vanderbilt Univ Med Ctr Nashville, Tennessee, United States, 37203 Less <<
NCT01215851 - Completed - -
NCT02099240 Osteomyelitis Early Phase 1 Recruiting September 2019 United States, Kentucky ... More >> University of Louisville Recruiting Louisville, Kentucky, United States, 40202 Contact: Julio A Ramirez, MD    502-852-1148    jarami01@louisville.edu    Contact: David Seligson, MD    502-852-0923    d0seli01@louisville.edu    Sub-Investigator: Forest Arnold, DO          Sub-Investigator: Timothy Wiemkwn, PhD          Sub-Investigator: Robert Kelley, PhD          Sub-Investigator: James Summersgill, PhD          Sub-Investigator: Ruth Carrico, PhD          Sub-Investigator: Julie Harting, PharmD          Sub-Investigator: Paula Peyrani, MD          Principal Investigator: David Seligson, MD          Sub-Investigator: Craig Roberts, MD          Principal Investigator: Julio Ramirez, MD Less <<
NCT03456102 Tuberculosis Phase 2 Not yet recruiting September 1, 2021 -
NCT02597621 - Recruiting December 2020 Germany ... More >> Research Center Borstel Recruiting Borstel, Schleswig-Holstein, Germany, 23845 Contact: Jan Heyckendorf, MD    +49-4537-188 ext 2901    jheyckendorf@fz-borstel.de    Sub-Investigator: Jan Heyckendorf, MD          Principal Investigator: Christoph Lange, MD Less <<
NCT00948077 Pulmonary Tuberculosis Not Applicable Unknown December 2011 Taiwan ... More >> Taipei Medical University- Wan Fang Hospital Recruiting Taipei, Taiwan, 116 Contact: Ming-Chih Yu, M.D.    +886-2-29307930 ext 52953    yutbc@ms10.hinet.net    Contact: Li-Chun Wu, MPH    +886-2-82300120    tar266@ms65.hinet.net    Principal Investigator: Ming-Chih Yu, M.D.          Sub-Investigator: H-Eugene Liu, PhD Less <<
NCT02042261 - Completed - Sweden ... More >> Dept of Infectious Diseases Linköping, Sweden, 581 85 Dept of Infectious Diseases, TB-unit, Karolinska Hospital Stockholm, Sweden, 17671 Less <<
NCT02840877 Tuberculosis ... More >>Alcohol Consumption Treatment Adverse Effect Less << Not Applicable Recruiting March 2021 South Africa ... More >> Worcester Community Day Centre Recruiting Worcester, Western Cape Province, South Africa Contact: Bronwyn Myers, PhD    27 21 9380993    Bronwyn.Myers@mrc.ac.za Less <<
NCT01225640 Tuberculosis Phase 2 Completed - South Africa ... More >> Pfizer Investigational Site Bellville, Cape Town, South Africa, 7530 Pfizer Investigational Site Cape Town, South Africa, 7700 Less <<
NCT06512831 Kidney Transplantation|Tubercu... More >>losis|Isoniazid Toxicity Less << COMPLETED 2024-03-01 West China Hospital, Sichuan U... More >>niversity, Chengdu, Sichuan, 610041, China Less <<
NCT03787940 Tuberculous Meningitis UNKNOWN 2021-12-31 Beijing Chest Hospital affilia... More >>ted to Capital Medical University, Beijing, China|Jiamusi Infectious Disease Hospital, Jiamusi, China|Jiangxi Provincial Chest Hospital, Nanchang, China|Zunyi Medical College affiliated Hospital, Zunyi, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

7.29mL

1.46mL

0.73mL

36.46mL

7.29mL

3.65mL

72.92mL

14.58mL

7.29mL

References

 

Historical Records

Categories